Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: A meta-analysis

Current Eye Research

Volumn 38, Issue 5, 2013, Pages 578-587

  Zhang, Yue ^a   Ma, Jinlan ^a   Meng, Nana ^a   Li, Hao ^a   Qu, Yi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bevacizumab; Diabetes; Macular edema; Meta analysis; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ARTICLE; CENTRAL MACULAR THICKNESS; DIABETIC MACULAR EDEMA; HUMAN; INTRAOCULAR PRESSURE; META ANALYSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE;

EID: 84875889898     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.767351     Document Type: Article

References (32)

1. Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, et al. Diabetic macular edema. Dev Ophthalmol 2010;47:73-110.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16.
3. Kook PE, Maier M, Schuster T, Feucht N, Lohmann CP. Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: A retrospective analysis. Acta Ophthalmol 2011;89:769-773.
4. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
5. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991;109:1549-1551.
6. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
7. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111:2044-2049.
8. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630.
9. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
10. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
11. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
12. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007;21: 245-257.
13. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-625.
14. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 2011;5:1011-1016.
15. Song JH, Lee JJ, Lee SJ. Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 2011;25:156-160.
16. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
17. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
18. Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: A randomized double-blind study. Acta Ophthalmol 2012;90:56-60.
19. Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin 2007;23:1253-1258.
20. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. Ann Intern Med 2009;151:264-269.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
23. Qian T, Li XX. Intravitreal injection of triamcinolone acetonide versus bevacizumab for diabetic macualr edema. Chin J Prac Ophthalmol 2010;28:1296-1299.
24. Wang LL, Zhang W, Li LJ, Jin LY, Huo M. Comparison of efficacy and safety between intraocular bevacizumab and triamcinolone for diabetic macualr edema. Chin J Exp Ophthalmol 2011;29:559-563.
25. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-1696.
26. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters 3rd GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
27. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146:508-512.
28. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
29. Fung AE, Bhisitkul RB. Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol 2008;92:1573-1574.
30. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
31. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.
32. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181 e2171.